TPBG and neoplasm: Compared with parental Tb535H, which is a bi-specific T cell engager targeting 5T4, the novel 53X tribodies not only retained similar binding properties of the parental Tb535H tribody, but showed enhanced anti-tumor potency by incorporating also checkpoint inhibition in a single molecule in addition to 5T4-mediated TCR/CD3 activation.